Rexahn Pharmaceuticals ( Rexahn Pharmaceuticals )

Rexahn Pharmaceuticals

Rexahn Pharmaceuticals's picture

About Rexahn Pharmaceuticals

Rexahn’s goal is to be a world leader in the discovery and development of new drugs to treat cancer. By developing compounds which specifically target cancer cells, but not healthy tissue, Rexahn’s drug candidates may demonstrate increased efficacy and reduced toxicity, efficacy against multiple drug resistant cancer cells and synergism with existing cytotoxic compounds. Utilizing a powerful, multi-faceted discovery engine consisting of small signaling molecule discovery, computational modeling, nanotechnology-based drug targeting and delivery, we believe that we are well on our way to achieving our goal.

Rexahn Pharmaceuticals press release, blog etc

06/14/2018 - 09:21 Rexahn Announces Adjournment of Annual Meeting of Shareholders until Wednesday
06/04/2018 - 09:10 Rexahn Pharmaceuticals Announces Presentations at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting
05/15/2018 - 07:43 Rexahn Phase 2a Combination Study of RX-3117 and Abraxane in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage
04/26/2018 - 05:16 Rexahn to Present Clinical Data at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
03/13/2018 - 07:39 Rexahn Pharmaceuticals to Present at Two Upcoming Conferences
03/12/2018 - 04:21 Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results
02/12/2018 - 06:09 Rexahn Reports Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Advanced Bladder Cancer at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting
02/08/2018 - 07:47 Rexahn Pharmaceuticals Announces Collaboration with Zhejiang Haichang Biotechnology Co., Ltd. for the Development of RX-0201 (Archexin) for the treatment of Hepatocellular Carcinoma
02/05/2018 - 09:24 Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting
01/29/2018 - 07:22 Rexahn Pharmaceuticals Receives Notice of Allowance for A New U.S. Patent Covering the Use of RX-5902 (Supinoxin)
01/22/2018 - 15:09 Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting
01/18/2018 - 16:36 Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting
01/08/2018 - 17:11 Rexahn Pharmaceuticals to Present at Biotech Showcase 2018
01/04/2018 - 07:24 Rexahn Pharmaceuticals Announces the Appointment of Douglas J. Swirsky as President and Chief Financial Officer
12/11/2017 - 09:32 Rexahn Pharmaceuticals Presents New Preclinical Data on Supinoxin at the 2017 San Antonio Breast Cancer Symposium
11/09/2017 - 10:52 Rexahn Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference
11/08/2017 - 08:17 Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Clinical Trial of RX-3117 in Combination with Abraxane in Patients Newly Diagnosed with Metastatic Pancreatic Cancer
10/13/2017 - 08:56 Rexahn Announces $8 Million Registered Direct Offering